These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27656775)

  • 21. Synthesis, crystal structure and antiproliferative activity of Cu(II) nalidixic acid-DACH conjugate: comparative in vitro DNA/RNA binding profile, cleavage activity and molecular docking studies.
    Arjmand F; Yousuf I; Hadda Tb; Toupet L
    Eur J Med Chem; 2014 Jun; 81():76-88. PubMed ID: 24826817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
    Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
    Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological activity of 2,4-di-p-phenolyl-6-2-furanyl-pyridine as a potent topoisomerase II poison.
    Karki R; Park C; Jun KY; Kadayat TM; Lee ES; Kwon Y
    Eur J Med Chem; 2015 Jan; 90():360-78. PubMed ID: 25437622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
    Park S; Kadayat TM; Jun KY; Thapa Magar TB; Bist G; Shrestha A; Lee ES; Kwon Y
    Eur J Med Chem; 2017 Jan; 125():14-28. PubMed ID: 27643560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors.
    Wambang N; Schifano-Faux N; Aillerie A; Baldeyrou B; Jacquet C; Bal-Mahieu C; Bousquet T; Pellegrini S; Ndifon PT; Meignan S; Goossens JF; Lansiaux A; Pélinski L
    Bioorg Med Chem; 2016 Feb; 24(4):651-60. PubMed ID: 26740155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
    Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-Flourophenyl-substituted 5H-indeno[1,2-b]pyridinols with enhanced topoisomerase IIα inhibitory activity: Synthesis, biological evaluation, and structure-activity relationships.
    Kunwar S; Hwang SY; Katila P; Seo M; Man Kadayat T; Kwon Y; Lee ES
    Bioorg Chem; 2021 Nov; 116():105349. PubMed ID: 34536927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
    Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.
    Karki R; Jun KY; Kadayat TM; Shin S; Thapa Magar TB; Bist G; Shrestha A; Na Y; Kwon Y; Lee ES
    Eur J Med Chem; 2016 May; 113():228-45. PubMed ID: 26945111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors.
    Karki R; Park C; Jun KY; Jee JG; Lee JH; Thapa P; Kadayat TM; Kwon Y; Lee ES
    Eur J Med Chem; 2014 Sep; 84():555-65. PubMed ID: 25062006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
    Park S; Thapa Magar TB; Kadayat TM; Lee HJ; Bist G; Shrestha A; Lee ES; Kwon Y
    Eur J Med Chem; 2017 Feb; 127():318-333. PubMed ID: 28068603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression.
    Daumar P; Zeglis BM; Ramos N; Divilov V; Sevak KK; Pillarsetty N; Lewis JS
    Eur J Med Chem; 2014 Oct; 86():769-81. PubMed ID: 25240701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIα inhibiting anticancer agent.
    Murugavel S; Ravikumar C; Jaabil G; Alagusundaram P
    Comput Biol Chem; 2019 Apr; 79():73-82. PubMed ID: 30731361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
    Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
    Pedatella S; Cerchia C; Manfra M; Cioce A; Bolognese A; Lavecchia A
    Eur J Med Chem; 2020 Feb; 187():111960. PubMed ID: 31869654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
    Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
    Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomeraseIIα and antitumor agents.
    Chen W; Shen Y; Li Z; Zhang M; Lu C; Shen Y
    Eur J Med Chem; 2014 Oct; 86():782-96. PubMed ID: 25240702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-
    Kadayat TM; Park S; Shrestha A; Jo H; Hwang SY; Katila P; Shrestha R; Nepal MR; Noh K; Kim SK; Koh WS; Kim KS; Jeon YH; Jeong TC; Kwon Y; Lee ES
    J Med Chem; 2019 Sep; 62(17):8194-8234. PubMed ID: 31398033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.